BOULDER, Colo., Oct. 3 -- Cardio-optics Inc. has completed a series of successful animal experiments of its patented Trans Blood Vision System. The experiments, conducted over a period of six weeks, verify that Cardio-optics' Trans Blood Vision technology, which uses infrared illumination, can see through flowing blood. This represents a major breakthrough for surgical procedures that require surgeons to work through blood, such as heart surgery and intravascular procedures.
"These experiments have confirmed the soundness of the technology and have established proof of concept in vivo," said Larry Blankenship, president and CEO of Cardio-optics. "We remain on track to have our first products ready for market late next year."
Cardio-optics medical director Bruce Ferguson said, "We have seen, for the first time, demonstration of the ability to see intracardiac structures in the presence of flowing blood in a live animal using infrared technology for visibility. He will present the results of these studies at the American Heart Association meeting in Anaheim, Calif., November.